Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Jackson

Pediatric Allergy/Immunology Madison, WI Medical Doctor

NPI 1003823923 CMS profile 619471

600 Highland Ave, Csc Box 9988, Madison, WI 53792

Open in the dashboard

General payments

$185,480

137 records reported · program years 2019–2025

Research payments

$20,778

Paid to them · 52 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$19,115,327 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Daniel Jackson of Madison, WI is reported in the CMS Open Payments database as having received $185,480 across 137 general payments and $20,778 in research payments paid to them. Separately, studies naming them as principal investigator received $19,115,327 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Pediatric Allergy/Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $38,499 16
2025 Research $1,250 1
2024 General $25,480 11
2024 Research $2,000 5
2023 General $21,048 15
2023 Research $3,750 11
2022 General $17,935 19
2022 Research $10,750 28
2021 General $22,392 11
2021 Research $1,500 4
2020 General $10,199 5
2020 Research $935 2
2019 General $49,927 60
2019 Research $593 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Jackson
  • Pediatric Allergy/Immunology median
  • Middle half of Pediatric Allergy/Immunology
  • National median

In program year 2025, general payments to Daniel Jackson were reported at $38,499. Among 289 Pediatric Allergy/Immunology profiles paid that year, the median was $361 and the middle half received between $125 and $2,493.

Show as a table
Year Daniel Jackson Pediatric Allergy/Immunology median Middle half National median
2019 $49,927 $325 $92–$1,399 $163
2020 $10,199 $144 $66–$2,490 $114
2021 $22,392 $357 $95–$2,633 $132
2022 $17,935 $385 $125–$2,259 $149
2023 $21,048 $470 $121–$2,946 $160
2024 $25,480 $317 $125–$2,583 $164
2025 $38,499 $361 $125–$2,493 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $75,265 43 payments
  2. Genzyme Corporation $38,627 31 payments
  3. Regeneron Pharmaceuticals, Inc. $25,233 13 payments
  4. AstraZeneca Pharmaceuticals LP $13,025 15 payments
  5. Regeneron Healthcare Solutions, Inc. $9,249 10 payments
  6. Chiesi USA, Inc. $8,475 1 payment
  7. Pfizer Inc. $6,475 8 payments
  8. Sanofi-Aventis U.S. LLC $5,381 6 payments
  9. Genentech USA, Inc. $1,800 1 payment
  10. AstraZeneca AB $1,275 8 payments
  11. Other $675 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $119,029 43 payments
  2. Travel and Lodging $52,270 36 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,250 10 payments
  4. Grant $2,500 2 payments
  5. Food and Beverage $2,431 46 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $30,113 21 payments
  2. DUPIXENT Immunology $18,160 9 payments
  3. DUPIXENT Immunology $16,217 16 payments
  4. NO PRODUCT DISCUSSED $7,881 8 payments
  5. NUCALA $7,800 13 payments
  6. EUCRISA $6,475 8 payments
  7. TEZSPIRE $5,639 2 payments
  8. FASENRA $5,089 9 payments
  9. DUPIXENT Immunology And Inflammation $4,369 2 payments
  10. Xolair $1,800 1 payment
  11. Other $675 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Genzyme Corporation $19,250 49 payments
  2. Sanofi-Aventis U.S. LLC $1,528 3 payments

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Allergy/Immunology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record